See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
1315 Capital is a private equity firm exclusively focused on investing in growth-stage healthcare companies. The firm partners with commercial-stage companies across four key healthcare verticals: healthcare services, pharma/medtech products, pharma/medtech outsourcing, and health & wellness. They invest in companies with proven business models and established product-market fit, partnering with management to build platforms of scale. Their platforms span founder- and family-owned businesses, institutionally backed companies, and corporate carve-outs. The firm targets $15 to $50 million equity investments in companies with potential to scale to $50 to $200 million in revenue, with strong margin potential and -$10 million to $10 million of EBITDA at time of investment. They offer flexibility for majority or minority ownership and focus on platforms with add-on M&A opportunities. Founded in 2014 by healthcare investment veterans Adele Oliva and Michael Koby, 1315 Capital was built on the premise that healthcare investing requires specialized expertise and successful partnerships require genuine collaboration.
Notable quotes
“Coating Place has a compelling opportunity to scale its best-in-class platform, offering highly specialized services and deep technical expertise for customers developing complex modified-release products. We're proud to partner with Tim and his team as the company expands its commercial reach.”
“The pharmaceutical industry increasingly needs spray-drying expertise in order to produce amorphous solid dispersions, drug substances, and functional excipients. We're proud to partner with Nicolas and the Codis team.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Coating Place | Growth Equity | — | 2026-01-14 |
| Codis | Growth Equity | — | 2025-10-16 |
| USpharma | Growth Equity | — | 2025-07-10 |
| SciSafe | Growth Equity | — | 2024-11-14 |
| Experic | Growth Equity | — | 2024-10-29 |
| Spineology | Growth Equity | $25m | 2024-08-06 |
| Primrose Bio | Growth Equity | — | 2024-08-06 |
| Biocoat | Growth Equity | — | — |
| Colorescience | Growth Equity | — | — |
| Reaction Biology | Growth Equity | — | — |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| BroadOak Capital Partners | 2 |
| Research Corporation Technologies | 1 |
| East Seattle Partners | 1 |
| Harro Höfliger Packaging Systems | 1 |
| Kineticos Ventures | 1 |
Fit check
Is 1315 Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit